Health Canada’s COVID-19 Vaccine Order Held up at Chinese Customs: What’s Going on?
Nearly two months ago, TrialSite News announced Canada was ready to sign a deal with China’s CanSino Biologics to supply […]
The COVID-19 Vaccine Race: Status update as of July 5 2020
Vaccine development, historically more of a marathon than a short distance sprint, becomes that and more in the COVID-19 pandemic-charged […]
EU starts to Get Serious about Buying COVID-19 Vaccines in Advance with $2.7b Fund & Trailing US, UK & Canada
European Union ambassadors on Wednesday met to declare, among other things, that the EU would use a $2.7 billion fund […]
Canadian Government Orders 37m Syringes for Future Vaccines
In a further sign of national vaccine planning readiness, Canada secured a contract to procure 37 million syringes—roughly the same […]
COVID-19 Vaccine Race Moves to Halifax as Canadian Volunteers Eager to Participate in CanSino Biologics Study of Ad5-nCoV
Just hours after an announcement by Justin Trudeau, Prime Minister of Canada, that the nation’s first COVID-19 vaccine clinical trial […]
CanSino Biologics Phase I Vaccine Results Look Promising
CanSino Biologics, technically in the lead of the vaccine race, was able to publish results of their Phase I clinical […]
CanSino Biologics to Embrace mRNA-based COVID-19 Vaccine Development—Some Considerations
CanSino Biologics is technically leading the pack of SARS-CoV-2 vaccine developers with its investigational Ad5-nCoV leveraging its adenovirus-based viral vector vaccine […]
Canada’s Center for Vaccinology Moves forward with CanSino Biologics’ Ad5-EBOV COVID-19 Vaccine Candidate
Health Canada authorized the first COVID-19 vaccine-focused clinical trial with Dalhousie University in Nova Scotia. Now that nation’s National Research […]
China’s CanSino Biologics & Canada National Government Consider Deal to Produce the Vaccine in Canada
Canadian researchers are working with China to develop a vaccine against SARS-CoV-2, the virus behind the COVID-19 pandemic. The two countries […]
